Venetoclax (Venclyxto®) in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||26/09/2018|
|Rapid review completed||18/10/2018|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of venetoclax compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||23/10/2018|
|Pre-submission consultation with Applicant||19/11/2018|
|Submission received from Applicant||03/01/2019|
|Preliminary review sent to Applicant||07/05/2019|
|NCPE assessment re-commenced||05/06/2019|
|Factual accuracy sent to Applicant||02/10/2019|
|NCPE assessment re-commenced||09/10/2019|
|NCPE assessment competed||08/11/2019|
|NCPE assessment outcome||The NCPE recommends that venetoclax in combination with rituximab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.*|
* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.